<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Increased Aurora kinase A gene copy number (AURKA-CN) has been reported in <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCRC), with unknown relationship to clinical outcome </plain></SENT>
<SENT sid="1" pm="."><plain>We correlated increased AURKA-CN in mCRC <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> with KRAS mutation status, overall and progression-free survival (OS, PFS).Methods:Sixty-one mCRC <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> were analysed for AURKA-CN using q-PCR, and KRAS mutation status by direct sequencing </plain></SENT>
<SENT sid="2" pm="."><plain>Expression of AURKA protein was analysed by immunohistochemistry </plain></SENT>
<SENT sid="3" pm="."><plain>Cox-proportional hazard method, Kaplan-Meier curves and log-rank statistics were used to estimate and compare the hazard ratios and median survival between the groups </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In <z:hpo ids='HP_0000001'>all</z:hpo>, 68% of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> exhibited high AURKA-CN, and 29% had a KRAS mutation, without correlation between the two </plain></SENT>
<SENT sid="5" pm="."><plain>Patients with high AURKA-CN <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> had longer median OS (48.6 vs 18.8 months, P=0.01), with stronger trend among KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> (median OS not reached vs 18.8 months, P=0.003) </plain></SENT>
<SENT sid="6" pm="."><plain>Progression-free survival was longer on first-line or second-line chemotherapy among patients with KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> and high vs low AURKA-CN (first: 17.6 vs 5.13 months, P=0.04; second: 10.4 vs 5.1 months, P=0.01) </plain></SENT>
<SENT sid="7" pm="."><plain>AURKA-CN level did not affect outcomes among patients with KRAS mutant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Increased AURKA-CN is common in mCRC <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> and is associated with longer OS and longer PFS during chemotherapy, particularly in KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
</text></document>